Per Hydbring

Publications
CV
Public outreach and news

Articles

Article: LUNG CANCER. 2023;182:107292
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(8):1678-1691
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort
Wang Q; Wang Y; Wang X; Nakamura Y; Hydbring P; Yamauchi Y; Zhao X; Cao M
Article: CANCERS. 2022;14(14):3430
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Kosibaty Z; Brustugun OT; Eide IJZ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Kazmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(3):182-201
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstrom M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson L-G
Article: METHODS IN MOLECULAR BIOLOGY. 2022;2445:171-182
Concepts and Design of Introducing Synthetic MicroRNAs into Mammalian Cells.
Hydbring P
Article: MOLECULAR ONCOLOGY. 2021;15(11):2941-2957
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage
Franzen B; Viktorsson K; Kamali C; Darai-Ramqvist E; Grozman V; Arapi V; Haag P; Kaminskyy VO; Hydbring P; Kanter L; Nyren S; Ekman S; De Petris L; Lewensohn R
Article: MSYSTEMS. 2021;6(3):e00175-e00121
A MicroRNA Gene Panel Predicts the Vaginal Microbiota Composition
Cheng L; Kazmierczak D; Norenhag J; Hamsten M; Fransson E; Schuppe-Koistinen I; Olovsson M; Engstrand L; Hydbring P; Du J
Article: CELL CYCLE. 2021;20(1):23-38
Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence
Bazzar W; Bocci M; Hejll E; Hogqvist Tabor V; Hydbring P; Grandien A; Alzrigat M; Larsson L-G
Article: METHODS IN MOLECULAR BIOLOGY. 2021;2329:81-94
Construction of a Full-Length 3'UTR Reporter System for Identification of Cell-Cycle Regulating MicroRNAs.
Kaźmierczak D; Hydbring P
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2019;511(2):260-265
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Article: LUNG CANCER. 2018;124:45-52
Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression
Hydbring P; De Petris L; Zhang Y; Branden E; Koyi H; Novak M; Kanter L; Haag P; Hurley J; Tadigotla V; Zhu B; Skog J; Viktorsson K; Ekman S; Lewensohn R
Article: SCIENTIFIC REPORTS. 2018;8(1):10064
A selective high affinity MYC-binding compound inhibits MYC: MAX interaction and MYC-dependent tumor cell proliferation
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson L-G
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2018;499(2):314-320
miR-126-5p targets Malate Dehydrogenase 1 in non-small cell lung carcinomas
Queiroz AL; Zhang B; Comstock DE; Hao Y; Eriksson M; Hydbring P; Vakifahmetoglu-Norberg H; Norberg E
Article: CELL CYCLE. 2017;16(23):2241-2248
Identification of cell cycle-targeting microRNAs through genome- wide screens
Hydbring P; Wang Y; Bogorad RL; Yin H; Anderson DG; Li C; Sicinski P
Article: ONCOTARGET. 2017;8(52):90225-90237
MYC is downregulated by a mitochondrial checkpoint mechanism
Zhang X; Mofers A; Hydbring P; Olofsson MH; Guo J; Linder S; D'Arcy P
Article: CELL REPORTS. 2017;19(11):2289-2303
PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis
Zhang B; Zheng A; Hydbring P; Ambroise G; Ouchida AT; Goiny M; Vakifahmetoglu-Norberg H; Norberg E
Article: CANCER CELL. 2017;31(4):576-590.e8
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Hydbring P; Wang Y; Fassl A; Li X; Matia V; Otto T; Choi YJ; Sweeney KE; Suski JM; Yin H; Bogorad RL; Goel S; Yuzugullu H; Kauffman KJ; Yang J; Jin C; Li Y; Floris D; Swanson R; Ng K; Sicinska E; Anders L; Zhao JJ; Polyak K; Anderson DG; Li C; Sicinski P
Article: ONCOTARGET. 2016;7(3):2837-2854
Interferon-γ-induced p27^KIP1 binds to and targets MYC for proteasome-mediated degradation
Bahram F; Hydbring P; Tronnersjo S; Zakaria SM; Frings O; Fahlen S; Nilsson H; Goodwin J; von der Lehr N; Su Y; Luescher B; Castell A; Larsson L-G
Article: DEVELOPMENTAL CELL. 2014;30(3):255-267
D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL.
Choi YJ; Saez B; Anders L; Hydbring P; Stefano J; Bacon NA; Cook C; Kalaszczynska I; Signoretti S; Young RA; Scadden DT; Sicinski P
Article: CANCER CELL. 2012;22(4):438-451
The requirement for cyclin D function in tumor maintenance.
Choi YJ; Li X; Hydbring P; Sanda T; Stefano J; Christie AL; Signoretti S; Look AT; Kung AL; von Boehmer H; Sicinski P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(4):E187-E196
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop
Menssen A; Hydbring P; Kapelle K; Vervoorts J; Diebold J; Luescher B; Larsson L-G; Hermeking H
Article: CANCER CELL. 2011;20(5):620-634
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
Anders L; Ke N; Hydbring P; Choi YJ; Widlund HR; Chick JM; Zhai H; Vidal M; Gygi SP; Braun P; Sicinski P
Article: AGING. 2010;2(4):244-250
Cdk2: a key regulator of the senescence control function of Myc
Hydbring P; Larsson L-G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2010;107(1):58-63
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring P; Bahram F; Su Y; Tronnersjo S; Hogstrand K; von der Lehr N; Sharifi HR; Lilischkis R; Hein N; Wu S; Vervoorts J; Henriksson M; Grandien A; Luscher B; Larsson L-G
Article: NATURE CELL BIOLOGY. 2010;12(1):54-59
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner S; Doni M; Hydbring P; Verrecchia A; Bianchi L; Sardella D; Schleker T; Perna D; Tronnersjo S; Murga M; Fernandez-Capetillo O; Barbacid M; Larsson L-G; Amati B
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(18):3099-3111
TGF-β enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity
Wu S; Hultquist A; Hydbring P; Cetinkaya C; Oberg F; Larsson L-G
Article: NATURE METHODS. 2006;3(12):995-1000
Direct observation of individual endogenous protein complexes in situ by proximity ligation.
Söderberg O; Gullberg M; Jarvius M; Ridderstråle K; Leuchowius K-J; Jarvius J; Wester K; Hydbring P; Bahram F; Larsson L-G; Landegren U
Article: NATURE CELL BIOLOGY. 2005;7(3):303-310
c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription
Arabi A; Wu SQ; Ridderstråle K; Bierhoff H; Shiue C; Fatyol K; Fahlén S; Hydbring P; Söderberg O; Grummt I; Larsson LG; Wright APH
Article: MOLECULAR CELL. 2003;11(5):1189-1200
The F-Box protein Skp2 participates in c-Myc protelosornal degradation and acts as a cofactor for c-Myc-regulated transcription
von der Lehr N; Johansson S; Wu SQ; Bahram F; Castell A; Cetinkaya C; Hydbring P; Weidung I; Nakayama K; Nakayama KI; Söderberg O; Kerppola TK; Larsson LG
Show more

All other publications

Editorial comment: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;13(9):0
Circulating tumor DNA (ctDNA)-the next generation biomarker in non-small cell lung cancer patients treated with immunotherapy?
Hydbring P
Editorial comment: FRONTIERS IN IMMUNOLOGY. 2024;15:1407748
Immune-mediated damage to the heart and lungs in autoimmune diseases
Wei L; Hydbring P; Long L
Editorial comment: TRANSLATIONAL LUNG CANCER RESEARCH. 2023;12(7):1358-1360
Targeting gene fusions in non-small cell lung cancer-a ceaseless success story?
Hydbring P
Editorial comment: TRANSLATIONAL LUNG CANCER RESEARCH. 2023;12(3):405-407
Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients
Hydbring P
Editorial comment: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(9):1739-1741
Complex glandular pattern as an independent predictor of survival probability in lung adenocarcinoma
Hydbring P
Review: DRUG DISCOVERY TODAY. 2017;22(9):1295-1301
Nanoparticles for immune system targeting
Du J; Zhang YS; Hobson D; Hydbring P
Review: GENES. 2017;8(7):E174-174
MYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring P; Castell A; Larsson L-G
Review: NATURE REVIEWS MOLECULAR CELL BIOLOGY. 2016;17(5):280-292
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases.
Hydbring P; Malumbres M; Sicinski P
Review: F1000RESEARCH. 2013;2:136
Clinical applications of microRNAs.
Hydbring P; Badalian-Very G
Review: CANCER RESEARCH. 2010;70(17):6687-6691
Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence
Hydbring P; Larsson L-G

Employments

Senior Research Specialist, Department of Oncology-Pathology, Karolinska Institutet, 2022-
Lecturer, Department of Oncology-Pathology, Karolinska Institutet, 2024-2025

Degrees and Education

Docent, Karolinska Institutet, 2023

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI